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Background: Our previous results showed that in
retinas from streptozotocin (STZ)-induced diabetic
rats there is an increased level of interleukin-1 b (IL-
1 b ). This cytokine may be involved in the expression
of the inducible isoform of the nitric oxide synthase
(iNOS), with consequent synthesis of large amounts
of NO and bloodÐretinal barrier (BRB) breakdown.
Aims: The aim of this work was to examine whether
the administration of cyclosporin-A (Cs-A) to STZ-
induced diabetic rats inhibits the synthesis of IL-1 b
and the expression of the inducible proteins, iNOS
and cyclo-oxygenase-2 (COX-2) in retinal cells, and
whether the activity of these proteins contribute to
BRB breakdown.
Methods: The level of IL-1 b was evaluated by ELISA
and the NO production by L-{3H}-citrulline formation.
Expression of iNOS and COX-2 proteins was deter-
mined by two methods, western blot and immunohis-
tochemistry. The permeability of the BRB was
assessed by quantification of the vitreous protein.
Results and discussion: Our results indicated that the
levels of IL-1 b and NO in retinas from Cs-A-treated
diabetic rats are significantly reduced, as compared to
that in non-treated diabetic rats. The treatment of
diabetic rats with Cs-A also significantly inhibited the
expression of the inducible proteins, iNOS and COX-
2. The evaluation of the vitreous protein content
revealed that Cs-A also reduces the BRB permeability.
Taken together, these results suggest that the
increased production of the inflammatory mediators,
IL-1 b and NO, in diabetes may affect the BRB permea-
bility and therefore contribute to the development of
diabetic retinopathy.
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Introduction
Homeostasis in the retina is regulated by the blood–
retinal barrier (BRB) which, among other physio-
logical functions, restricts the movement of mole-
cules and minimizes leukocyte migration into the
retina.1,2 In diabetic retinopathy, the integrity of the
BRB is altered,1,3,4 which leads to visual loss by
mechanisms that are not well understood.
Results from our previous work suggested that in
streptozotocin (STZ)-induced diabetic rats the
increased BRB permeability may be the consequence
of an increased expression of the inducible isoform of
the enzyme nitric oxide synthase (iNOS).5 In addition
we also found that, in retinas from diabetic rats, there
was an increased level of interleukin-1b (IL-1b) and
prostaglandin E2 (PGE2).6,7 These findings are in
agreement with other studies showing that IL-1b
induces the expression of iNOS and of cyclo-oxy-
genase-2 (COX-2) in b-cells from Langerhans islets of
diabetic animals, leading to cell death and to islet
destruction.8,9 It was also observed that an intraocular
injection of IL-1b in Wistar rats causes disruption of
the BRB10 and in the BB/Edinburgh rats, an animal
model of insulin-dependent diabetes, cyclosporin A
(Cs-A) reduces b cell destruction and prevents the
development of diabetes.11
In this work, Cs-A, an anti-inflammatory drug that
inhibits IL-1b production,12 was used to investigate
whether the increase of IL-1b synthesis that occurs in
STZ-induced diabetic rats modulates both the expres-
sion of the inducible proteins iNOS and COX-2 in the
retinal cells and the BRB permeability.
Material and methods
Chemicals
STZ (60 mg/ml/kg) and the kit for protein quantifica-
tion were purchased from Sigma Chemical Co., St
Louis, USA. Cs-A (10 mg/kg/day) was from Sandoz and
the kit for quantification of Cs-A was from Abbott
Laboratories (Lisboa, Portugal). The kit for IL-1b
quantification was purchased from R&D Systems,
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Oxon, UK. L-[3H]-arginine was purchased from Amer-
sham, Bucks, UK. Dowex AG 50W-X8 was obtained
from BioRad, Herts, UK. The kit for glucose quantifica-
tion was purchased from Boheringer, East Sussex, UK.
The antibody anti-iNOS was purchased from Transduc-
tion Laboratories, Lexington KY, USA and the antibody
anti-COX 2 was from Santa Cruz, CA, USA. The
antibody anti-actin was from Boheringer, East Sussex,
UK. The secondary antibodies anti-rabbit and anti-rat
were from Dako, Copenhagen, Denmark and the anti-
goat was from Boheringer, East Sussex, UK. All other
chemicals used in this study were of analytical grade.
Animals
Twenty male Wistar rats (250–300 g body weight)
were anesthetized with ether and injected perito-
neally with a freshly prepared solution of STZ (60 mg/
ml/kg in 0.1 M citrate buffer, pH=4.5), ten of them
started treatment with Cs-A (10 mg/kg/day) on the
same day. Twenty normal rats were injected with an
equal volume of 0.1 M citrate buffer and ten of them
also started treatment with Cs-A (10 mg/kg/day).
All animals were assessed regularly for weight, blood
glucose and glycosuria. The blood glucose levels were
checked with a colorimetric method based on a
standard method, and glycosuria was assessed with
glucose oxidase reagent strips. The criteria for diabetes
were persistent hyperglycemia (>350 mg/100 ml), gly-
cosuria, polyuria and impaired growth according to
the results previously obtained.4
The Cs-A-treated animals were also assessed daily
for blood Cs-A which was determined according to
the kit instructions.
Eight days after the induction of diabetes the animals
were anesthetized, the eyes were removed and the
retinas peeled off without the retinal pigment epithe-
lium. Since the development of the retinal alterations
due to diabetes is not symmetrical each eye was
analysed independently. For each experiment five
normal rats, five Cs-A-treated normal rats, five diabetic
rats and five Cs-A-treated diabetic rats were used.
In all the experiments the animals were treated
according to the statements of the ‘Association for
Research in Vision and Ophthalmology.’
Assay for IL-1b measurement
To quantify the retinal levels of IL-1b the retinas were
washed and sonicated in the diluent calibrator of the
kit. The level of IL-1b was then determined by ELISA
according to the kit instructions.
Measurement of nitric oxide synthase activity
To determine the NOS activity the retinas were
washed and sonicated in HEPES buffer (20 mM, pH =
7.4). The NOS activity was determined in the retinal
lysates by measuring the formation of L-[3H]-citrulline
from L-[3H]-arginine, as previously described.5 Briefly,
retinal lysates (0.5 mg protein/ml) were incubated for
30 min, at 37°C, in a total volume of 200ml of an
incubation medium containing 0.5 mM NADPH,
2 mM Ca2+, 1 mM EGTA and 10 nM L-[3H]-arginine
(60 Ci/mmol). The enzymatic reactions were initiated
by addition of retinal lysates to the incubation
medium and the assays were terminated using 1.8 ml
of STOP solution (50 mM HEPES, pH 5.5, 5 mM
EDTA, at 4°C). The L-[3H]- citrulline was separated
from L-[3H]-arginine on Dowex AG 50W-X8 (Na+
form) columns previously equilibrated with STOP
solution. The L-[3H]-citrulline was eluted with 2 ml of
distilled water, and the radioactivity was quantified by
liquid-scintillation counter.
Western blot analysis
For immunodetection of iNOS and COX-2, retinas were
sonicated in 200ml of lysis buffer (phosphate-buffered
saline containing 10 mM EDTA, 1% Triton X-100 and
the protease inhibitor cocktail). In brief, protein
samples (25mg protein of retinal lysate) were sepa-
rated on a 10% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and transferred to a polyvinylidene
difluoride membrane. The membrane was blocked
with 5% dry milk in Tris-buffered saline with 0.1%
Tween 20 (TBST) for 1 h. The levels of iNOS protein
were detected using a 1:2000 dilution of a rabbit
polyclonal anti-mouse iNOS antibody for 1 h, followed
by incubation with a 1:1000 dilution of the horseradish
peroxidase-conjugated anti-rabbit antibody for 1 h. The
levels of COX-2 were determined using a 1:500
dilution of goat polyclonal anti-rat COX-2 antibody for
1 h, followed by incubation with a 1:1000 dilution of
horseradish peroxidase-conjugated anti-goat antibody
for 1 h. The immunocomplexes were visualized by the
ECL chemiluminiscence method. Subsequently, the
relative expression of iNOS was analysed by a
computer program (Adobe Photoshop, IBM) and a
densitometric analysis was performed using the
ImageQuant software (Molecular Dynamics Inc., Sun-
nyvale, CA). To ensure that the loading of protein was
equivalent, the membranes were stripped and repro-
bed with anti-actin antibody (1:10000).
Immunohistochemical localization of iNOS
For immunohistochemical detection of iNOS, the
animals were killed and the eyes removed and fixed
for 24 h in 4% paraformaldehyde in 0.1 M Na phos-
phate buffer, pH 7.4 at 4°C. Eyes were then dehy-
drated through a graded series of alcohols, embedded
in paraffin and 5-mm thick sections were cut.
Immunohistochemistry was performed on sections
pre-incubated in phosphate-buffer saline containing
normal rabbit serum (1:20). For localization of iNOS,
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eye sections were incubated for 2 h at room tem-
perature with polyclonal anti-iNOS (2.5mg/ml)
diluted in phosphate-buffer saline and then incubated
for 45 min at room temperature with fluorescein
swine anti-rabbit (1:20) diluted in phosphate-buffer
saline. Control procedures included the study of eye
sections without the primary antibody.
Evaluation of BRB permeability
The permeability of BRB was measured by quantifica-
tion of the vitreous protein concentration according
to the method described by Berkowitz and co-
workers.13 Briefly, the eyes were removed and
vitreous samples dissected into 10 mM phosphate-
buffer saline. After the removal of the samples they
were frozen at –70°C. On the day of protein
measurement, the vitreous was thawed to room
temperature, sonicated and centrifuged for 30 min at
10,000 g. Protein levels were measured, using the
Sigma protein assay kit with 25ml of sample in 200ml
of assay reagent for 30 min at 37°C, before reading the
absorbance at 550 nm. Protein concentrations were
determined using the Sigma protein assay kit, and
standards of albumin. The vitreous from all rats was
weighted to determine whether it had been losing
water due to the hyperosmolarity developed by
hyperglycemia, but no differences were found.
Statistics
All data are presented as mean ± SD of at least five
separate experiments. Statistical analyses was per-
formed using one-way ANOVA analysis and Dunnett’s
test. The confidence interval was 95%.
Results
Effect of Cs-A on IL-1b concentration
Eight days after the induction of diabetes by STZ all
the diabetic animals, treated and non-treated with Cs-
A, developed hyperglycemia (above 350 mg/100 ml),
increased polyuria and decreased body weight. In
both types of animals, normal rats treated and non-
treated with Cs-A, the glycemia was lower than
95 mg/100 ml.
Quantification of the Cs-A concentration in serum
and in retinas showed that in normal and diabetic rats
treated with Cs-A, the serum concentration of Cs-A
was higher than 1500 ng/ml and the retinal concentra-
tion of Cs-A was higher than 200 ng/ml, which have
been considered therapeutical levels.14
As indicated in Fig. 1 the levels of IL-1b in retinal
lysates from Cs-A-treated diabetic rats were sig-
nificantly reduced (0.17 ± 0.014 pg/mg protein)
compared to those in non-treated Cs-A diabetic rats
(0.31 ± 0.08 pg/mg protein), p < 0.05. The level of
IL-1b did not differ significantly between the Cs-
A-treated and non-treated normal rats.
Effect of Cs-A on nitric oxide synthase activity
The activity of NOS in retinal lysates was evaluated by
the conversion of L-[3H]-arginine to L-[3H]-citrulline.
As indicated in Fig. 2, in Cs-A-treated diabetic rats the
production of L-[3H]-citrulline was significantly
reduced (175±19.5 pmol L-citrulline/mg protein/
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FIG. 1. Level of IL-1b in retina. The levels of IL-1b were
determined in retinal lysates according to the kit instructions.
Data are mean ± SD values from 5 rats from each group.
*Significant differences from normal rats. **Significant
differences from Cs-A non-treated diabetic rats (p>0.05)(one-
way ANOVA analysis, Dunnett’s test).
FIG. 2. Measurements of NOS activity in retina. Retinal lysates
(0.5 mg protein/ml) were incubated in a medium containing
1 mM EGTA, 0.5 mM NADPH and 10 nM L- [3H]-arginine in the
presence or absence of 2 mM Ca2+ , in a total volume of 200ml.
The NOS activity was measured by the formation of L-[3H]-
citrulline. Data are mean ± SD values from 5 rats from each
group. *Significant differences from normal rats. ** Sig-
nificant differences from Cs-A non-treated diabetic rats
(p<0.05) (one-way ANOVA analysis, Dunnett’s test).
30 min) compared to that in non-treated diabetic rats
(270±215 pmol L-citrulline/mg protein/30 min),
p<0.05. The production of L-[3H]-citrulline did not
differ significantly between the Cs-A-treated and non-
treated normal rats.
Effect of Cs-A on iNOS expression
To determine whether Cs-A reduces NOS activity by
inhibiting iNOS expression we examined the amount
of iNOS protein content by Western blot analysis in
retinal lysates (Fig. 3) and the localization of iNOS
protein by imunohistochemistry in retinal sections.
As indicated in Fig. 3A, the Western blot analysis
showed that in retinas from Cs-A-treated diabetic rats
(Fig. 3A, Lane 4) the amount of iNOS protein
(130.6 kDa) decreased compared to that in retinas
from Cs-A non-treated diabetic rats (Fig. 3A, Lane 3).
Similar amounts of iNOS protein were detected in
both treated and non-treated Cs-A normal rats (Fig.
3A, Lanes 1 and 2). These results indicate that in
retinas from normal rats iNOS protein is constitutively
expressed. As indicated in Fig. 3B the densitometric
analysis revealed a significant decrease of iNOS
protein content in retinas from Cs-A-treated diabetic
rats (154.45±22.8 optical density) compared to that in
retinas from Cs-A non-treated diabetic rats (96.0±10.5
optical density), p<0.05.
The immunolocalization of iNOS showed that in
non-treated Cs-A diabetic rats, iNOS protein was
clearly detected in the outer nuclear layer, inner
nuclear layer, inner plexiform layer and also at the
ganglion cell layer (Fig. 4C). In Cs-A-treated diabetic
rats (Fig. 4D), iNOS protein remained localized at the
inner nuclear and at the ganglion layer although the
number of cells stained for iNOS in both retinal cell
layers decreased compared to that in Cs-A non-treated
diabetic rats. In retinas from Cs-A treated and non-
treated normal rats iNOS protein was slightly
expressed at the inner nuclear layer which explains
the reduced amount of iNOS protein detected by
Western blot (Fig. 4A, B).
Effect of Cs-A on COX-2 expression
To determine whether Cs-A reduces the expression of
COX-2 protein we evaluated the amount of COX-2
protein by Western blot (Fig. 5). The results revealed
that in retinas from Cs-A-treated diabetic rats (Fig. 5A,
Lane 4) the amount of COX-2 protein decreased
compared to that in retinas from Cs-A non-treated
diabetic rats, (Fig. 5A, Lane 3). Similar amounts of
COX-2 protein were detected in treated and non-
treated Cs-A normal rats (Fig. 5A, Lanes 1 and 2). The
data from the densitometric analysis of the blots
confirmed that in Cs-A-treated diabetic rats there was
a significant decrease (103.5±9.7 optical density) in
COX-2 protein content compared to that in retinal
lysates from Cs-A non-treated diabetic rats
(143.7±16.4 optical density), p<0.05, Fig. 5B.
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FIG. 3. Study of the expression of iNOS protein. (A) Western
blot for detection of iNOS protein expression in retina.
Retinal lysates were subjected to electrophoresis followed
by immunoblotting with a polyclonal antibody against iNOS.
Lane 1: retinal lysate from normal rats; Lane 2: retinal lysate
from Cs-A treated normal rats; Lane 3: retinal lysate from
diabetic rats; Lane 4: retinal lysate from diabetic rats. This
figure is representative of 5 identical experiments. (B)
Densitometric analysis of iNOS expression. Anti-actin was
used to ensure that the protein loading was equivalent. Data
are mean ± SD values from 5 rats from each group.
*Significant differences from normal rats. **Significant
differences from Cs-A non-treated diabetic rats (p<0.05)
(one-way ANOVA analysis, Dunnett’s test).
FIG. 4. Immunohistochemical localization of iNOS in intact
retina. Retinal sections from normal and diabetic rats were
incubated with the same anti-iNOS antibody used for the
Western blot analysis. In control experiments retinal sections
were only incubated with the secondary antibody. (A) retinal
section from normal rats; (B) retinal section from Cs-
A-treated normal rats; (C) retinal section from diabetic rats;
(D) retinal section from Cs-A-treated diabetic rats. Magnifica-
tion 20´ .
Effect of Cs-A on BRB permeability
In Cs-A non-treated diabetic rats there was a sig-
nificant increase in vitreous protein concentration
(3.10±0.28 mg/ml of vitreous protein) compared to
that in Cs-A non-treated normal rats (1.1±0.17 mg/ml
of vitreous protein), p<0.01 (Fig. 6). These results
indicated that in Cs-A non-treated diabetic rats the
permeability of BRB is significantly increased.
Cs-A-treated diabetic rats showed a significant
decrease in vitreous protein concentration (1.31 ±
0.17 mg/ml of vitreous protein) compared to that in
Cs-A non-treated diabetic rats (3.10±0.28 mg/ml of
vitreous protein), p<0.01 (Fig. 5), which indicated
that Cs-A reduces the BRB permeability in diabetic
rats.
Discussion
In our previous studies, we observed that there was a
breakdown of the BRB in STZ-induced diabetic rats
which appeared to be correlated with an increased
level of NO and IL-1b in retinas from STZ-induced
diabetic rats.4 – 6 In this study, we investigate whether
the inhibition of IL-1b synthesis by Cs-A affects the
expression of iNOS and COX-2 proteins, and we
correlate those results with the BRB permeability.
Cs-A reduced the level of IL-1b in retinas from Cs-
A-treated diabetic rats. This result is in agreement with
previous studies reporting that Cs-A inhibits IL-1b
synthesis either in vitro, such as in rat renal mesan-
glial cells15 or in vivo as evaluated in atymic rats.12
The treatment of STZ-induced diabetic rats with Cs-
A significantly reduced the NO production in retinas,
which seemed to be associated with a decreased
expression of iNOS protein. Other studies report that
in mesanglial cells, Cs-A inhibits the IL-1b-dependent
transcriptional up-regulation of the iNOS gene by
inhibiting the activation of the transcription factor
NF-kB.15 Therefore, the decreased production of NO
in retinas from Cs-A-treated diabetic rats, as indicated
in Fig. 2, may be due to the inhibition of the cellular
mechanism that controls the expression and the
activity of iNOS.
We have previously observed that in eight-days STZ-
induced diabetic rats the main alteration of the BRB
permeability was localized at the retinal vessels and
that the iNOS protein was mainly expressed at the
inner nuclear layer.4,16 Since the treatment of diabetic
rats reduces the expression of iNOS protein which is
accompanied by a significant reduction of the BRB
permeability, it appears that the increased production
of NO around the retinal vessels may affect retinal
vessel permeability.
The COX-2 protein level in retinas from diabetic rats
non-treated with Cs-A is increased compared to that in
normal rats whereas in retinas from diabetic rats
treated with Cs-A it is significantly reduced (Fig. 5).
These results are in agreement with previous studies
reporting that the expression of COX-2 could be
induced by the cytokine IL-1b and by NO17,18 and that
in rat mesanglial cells, IL-1b-induced COX-2 expression
was suppressed by Cs-A.19 The up-regulation of COX-2
Cyclosporin-A and blood–retinal barrier permeability
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FIG. 5. Study of the expression of COX-2 protein. (A) Western
blot for detection of COX-2 protein expression in retina. Lane
1: retinal lysate from normal rats; Lane 2: retinal lysate from
Cs-A-treated normal rats; Lane 3: retinal lysate from diabetic
rats; Lane 4: retinal lysate from diabetic rats. This figure is
representative of 5 identical experiments. (B) Densitometric
analysis of COX-2 expression. Anti-actin was used to ensure
that the protein loading was equivalent. Data are mean ± SD
values from 5 rats from each group. *Significant differences
from normal rats. **Significant differences from Cs-A non-
treated diabetic rats (p<0.05) (one-way ANOVA analysis,
Dunnett’s test).
FIG. 6. Vitreous protein concentration. The protein concen-
tration was determined according to the kit instructions. Data
are mean ± SD values from 5 rats from each group.
*Significant differences from normal rats (p<0.05). **Sig-
nificant differences from Cs-A non-treated diabetic rats
(p<0.05) (one-way ANOVA analysis, Dunnett’s test).
expression leads to an increased production of
prostaglandins, which may act as vasodilatory and
inflammatory mediators.20,21 Therefore, in the animal
model of diabetes used in this work, COX-2 protein
expression together with increased production of NO
may be involved in the BRB breakdown.
Cs-A decreases the vitreous protein concentration
in diabetic rats compared to that in diabetic rats non-
treated with Cs-A (Fig. 6), which indicates that Cs-A
causes a reduction of the BRB permeability.
In conclusion, the results from our study indicate
that Cs-A reduces the BRB permeability in STZ-
induced diabetic rats. The effect of Cs-A in the BRB
permeability appears to be related to a down-
regulation of pro-inflammatory cytokines IL-1b and
NO as well as to the down-regulation of the expres-
sion of iNOS and COX-2 proteins.
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